Pulmonary hypertension: physiologic or pathologic disease?
Soifer
S J
SJ
Cardiovascular Research Institute, University of California, San Francisco 94143.
D000109:Acetylcholine / Q000502:physiology; D000255:Adenosine Triphosphate / Q000502:physiology; D001706:Biopsy; D001794:Blood Pressure; D001809:Blood Viscosity; D002648:Child; D004730:Endothelium, Vascular / Q000378:metabolism; D006801:Humans; D006965:Hyperplasia; D006976:Hypertension, Pulmonary / Q000097:blood / Q000473:pathology* / Q000503:physiopathology* / Q000628:therapy; D006984:Hypertrophy; D007223:Infant; D007231:Infant, Newborn; D009131:Muscle, Smooth, Vascular / Q000473:pathology*; D009569:Nitric Oxide / Q000494:pharmacology / Q000627:therapeutic use; D010547:Persistent Fetal Circulation Syndrome / Q000097:blood / Q000473:pathology* / Q000503:physiopathology* / Q000628:therapy; D011651:Pulmonary Artery / Q000473:pathology*; D011652:Pulmonary Circulation; D014655:Vascular Resistance; D014665:Vasodilator Agents / Q000627:therapeutic use
D014665:Vasodilator Agents; D009569:Nitric Oxide; D000255:Adenosine Triphosphate; D000109:Acetylcholine